New drug tested in people with liver disease
NCT ID NCT05891158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for side effects, not to treat the liver condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRU Hungary Kft
Kistarcsa, 2143, Hungary
-
Summit Clinical Research s.r.o.
Bratislava, 851 05, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, Slovakia
-
Summit Clinical Research s.r.o.
Nové Zámky, 940 34, Slovakia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug